Hormone-refractory prostate cancer: an evolving standard of care.
about
Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI.A potential oncogenic activity of platelet-derived growth factor d in prostate cancer progressionMiR-29a suppresses prostate cell proliferation and induces apoptosis via KDM5B protein regulationEvaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID miceIdentification of androgen-responsive lncRNAs as diagnostic and prognostic markers for prostate cancer
P2860
Hormone-refractory prostate cancer: an evolving standard of care.
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Hormone-refractory prostate cancer: an evolving standard of care.
@ast
Hormone-refractory prostate cancer: an evolving standard of care.
@en
type
label
Hormone-refractory prostate cancer: an evolving standard of care.
@ast
Hormone-refractory prostate cancer: an evolving standard of care.
@en
prefLabel
Hormone-refractory prostate cancer: an evolving standard of care.
@ast
Hormone-refractory prostate cancer: an evolving standard of care.
@en
P2093
P1433
P1476
Hormone-refractory prostate cancer: an evolving standard of care
@en
P2093
N J Vogelzang
P433
5 Suppl 17
P577
1999-10-01T00:00:00Z